Fight Cancer With Our Breakthrough Drug Prediction Platform – DxPP
Fight Cancer With Our Breakthrough Drug Prediction Platform – DxPP
Discover the difference our first-in-kind AI and therapy resistant cell technologies bring to treatment planning and drug development for cancer patients.
Discover the difference our first-in-kind AI and therapy resistant cell technologies bring to treatment planning and drug development for cancer patients.
First Ascent’s Ex Vivo Drug Response Identification & Validation Engine – xDRIVE Platform is a first-in-kind medical oncology decision support system that integrates functional drug testing, DNA/RNA sequencing and AI-guided tumor weakness mapping resulting in prioritized therapeutic solutions tailored to the patient’s tumor vulnerabilities and validated through tests run on the patient’s own cells.
Publication and Pharma Partners
The Latest First Ascent Biomedical News
ERIE, Pa. (March 26, 2025) -- Gannon University, Saint Vincent Hospital and First Ascent Biomedical [...]
First Ascent Biomedical Awarded Florida Cancer Innovation Fund Grant Grant Focused on Advancing Precision Cancer [...]
CancerX is a groundbreaking public-private partnership designed to accelerate innovation in the fight against cancer. [...]